Liquid biopsy screening for esophageal adenocarcinoma

Esophageal adenocarcinoma (EAC) accounts for the majority of esophageal cancer in most industrialised countries. QIMR Berghofer Associate Professor Michelle Hill has developed a minimally-invasive liquid biopsy test for early detection of EAC.

Unique selling point/competitive advantage

Diagnosis of EAC at earlier stages improves 5-year survival rates dramatically, with detection at the high grade dysplasia/T1a cancer stage treatable endoscopically. A cost-effective liquid biopsy can be used to identify individuals at earlier stages of EAC. This reduces the number of endoscopy procedures required, with endoscopy scheduled only after a positive blood test.

Investment or collaboration opportunities

QIMR Berghofer seeks industry partners to help develop this technology onto a commercially and clinically feasible molecular diagnostics platform (i.e. assay development). The partner/s would also be required to take a developmental lead in clinical study and regulatory approval aspects.

Intellectual property rights

QIMR Berghofer is the commercialisation lead of associated formal intellectual property, which entered national/regional phase in Australia, Canada, China, Europe and the US in 2017.

Contact

David Cash
Phone: +61 7 3362 0179
Email: david.cash@qimrberghofer.edu.au

More information

Visit QIMR Berghofer for more information.

Also consider...